期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性乙型肝炎治疗路线图的评价——应答指导的临床治疗策略 被引量：1

Evaluation on "Roadmap" of Chronic Hepatitis B Therapy—Respond Guide Treatment Strategy
下载PDF
导出
摘要 慢性乙型肝炎治疗路线图是根据患者对抗病毒药物应答的不同、用病毒及其抗原水平在治疗的整个过程中对患者进行科学管理、制定治疗策略、确定治疗时间的一种优化治疗方案。本文将从它的可行性和意义、重要性、治疗策略的确定及在临床上应用的局限性等方面进行论述。 ＂Roadmap＂ of chronic hepatitis B therapy is a optimized clinical strategy for patient with chronic hepatitis B management after received anti--virus therapy on response to anti--virus drugs. The followings are summery on its feasibility, significance, treatment strategy and localized in clinical practice.
作者 窦晓光 丁洋
机构地区 中国医科大学附属盛京医院感染科
出处 《医学与哲学（B）》 2009年第5期7-8,共2页 Medicine & Philosophy(B)
关键词 乙型肝炎 治疗策略 路线图 Hepatitis B, treatment strategy, roadmap
分类号 R512.62 [医药卫生—内科学]
  • 相关文献

参考文献8

  • 1Di Bisceglie A M,Lai C L,Gane E,et al.Telbivudine GLOBE tri-al:Maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients[].Hepatology.2006
  • 2Keeffe EB,Zeuzem S,Koff RS,et al.Report of an international workshop:Roadmap for management of patients receiving oral therapy for chronic hepatitis B[].Clinics in Gastroenterology.2007
  • 3Lai CL,Gane E,Liaw YF,et al.Telbivudine versus lamivudine in patients with chronic hepatitis B[].The New England Journal of Medicine.2007
  • 4Hou J,Yin YK,Xu D,et al.Telbivudine versus lamivudine in Chi-nese patients with chronic hepatitis B:Results at 1 year of arandomized,double-blind trial[].Hepatology.2007
  • 5Zeuzem S,Buti M,Gane EJ,et al.Baseline Parameters PredictBoth Early Virologic Response And Longer TermOutcomes For Telbi-vudine-Treated Patients With Chronic Hepatitis B(The GLOBEStudy)[].Hepatology.2007
  • 6Reddy KR,Rustgi V,Zeuzem S,et al.Week 24 is the OptimalTime Point for Predicting Outcomes at2 Years with Telbivudine[].Global Antiviral J.2007
  • 7Standring DN,Patty A,Chapron C,et al.Resistance Determinationin Patients Experiencing Virologic Breakthrough Following Telbivudi-ne or Lamivudine Therapy in the International GLOBE Trial[].DDW.2007
  • 8Gane E,Lai CL,Min A,et al.Adefovir salvage therapy for virologic breakthrough in Telbivudine-treated patients from the GLOBE study[].Journal of Hepatology.2007

同被引文献9

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
  • 2贾继东,侯金林,尹有宽,徐道振,谭德明,牛俊奇,周霞秋,王宇明,朱理珉,贺永文,任红,万谟彬,陈成伟,巫善明,陈亚岗,许家璋,王勤环,魏来,马红.替比夫定或拉米夫定抗乙型肝炎病毒的疗效预测探讨[J].中华肝脏病杂志,2007,15(5):342-345. 被引量：141
  • 3Keeffe EB, Zeuzem S, Keff RS, et al. Report of international workshop: Roadmap for management of patientsreceiving oral therapy for chronic hepatitis B[J]. Clin Gastroenteral Hepatol, 2007, 5(8): 890-897.
  • 4Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States:an update[J]. Clin Gastroenterol Hepatol, 2006, 4(8): 936-962.
  • 5Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology, 2007, 45(2): 507-539.
  • 6Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B[J]. Gastroenterology, 2009, 136(2): 486- 495.
  • 7Nash K. Telbivudine in the treatment of chronic hepatitis B[J]. Adv Ther, 2009, 26 (2): 155-169.
  • 8DiBisceglie A, Lai CL, Gane E, et al. Telbivudine GLOBE trial Maximal early HBV suppression is predictive of optimal two- year efficacy in nucleoside treated hepatitis B patients [J] Hepatology, 2006, 44(Suppl 1): 230A-231A.
  • 9韩蓓,汪荣生,张军.替比夫定可作为慢性乙型肝炎患者一线治疗[J].哈尔滨医药,2008,28(2):18-19. 被引量：12

引证文献1

二级引证文献4

医学与哲学（B）
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部